Pfizer to Cut U.S. Sales Force by 20%

Pfizer said Tuesday it will trim its U.S. sales force by 20% as part of an ongoing review process announced in October.

Pfizer said it will provide more details, including a long-term outlook and additional reorganization moves, in January.

'Consistent with Pfizer's long-standing values, we will provide affected employees with support services and benefits during their transitions,' Ian Read, president of Pfizer worldwide pharmaceutical operations, said in a statement. 'We will continue to support and reward our top performers.'

The company said it will maintain strong support for products including Lipitor, Celebrex, Geodon, Lyrica, Exubera, Chantix and Sutent.

Contact U.S. News


    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More

Don't Miss

U.S. Video